Go Pro
→ Now that SpaceX is public, buy this ticker (no, not SpaceX or Tesla) (From Brownstone Research) (Ad)tc pixel Free CANC Stock Alerts

Tema Oncology ETF (CANC) Short Interest Ratio & Short Volume

$42.33 -0.22 (-0.52%)
As of 12:15 PM Eastern
Compare

Tema Oncology ETF Short Interest Overview

As of July 31, 2026, Tema Oncology ETF (CANC) had a short interest of 20,291 shares sold short, representing 0.43% of the public float. This marks a -11.10% decrease in short interest since the prior report. The short interest ratio (days to cover) is 0.9, meaning it would take 0.9 days of the average trading volume of 32,138 shares to cover all short positions.

Current Short Interest
20,291 shares
Previous Short Interest
22,825 shares
Change Vs. Previous Month
-11.10%
Dollar Volume Sold Short
$824.83 thousand
Short Interest Ratio
0.9 Days to Cover
Last Record Date
July 31, 2026
Outstanding Shares
4,770,000 shares
Short Percent of Float
0.43%
Today's Trading Volume
4,779 shares
Average Trading Volume
32,138 shares
Today's Volume Vs. Average
15%
Short Selling Tema Oncology ETF?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Tema Oncology ETF and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

CANC Short Interest Over Time

CANC Days to Cover Over Time

CANC Percentage of Float Shorted Over Time

Tema Oncology ETF Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/31/202620,291 shares $824.83 thousand -11.1%0.4%0.86 $40.65
7/15/202622,825 shares $933.77 thousand -16.9%0.5%0.54 $40.91
6/30/202627,461 shares $1.13 million +79.6%0.6%0.41 $41.24
6/15/202615,293 shares $573.03 thousand +37.9%0.3%0.59 $37.47
5/29/202611,090 shares $422.42 thousand -30.5%0.2%0.82 $38.09
5/15/202615,952 shares $591.66 thousand +85.4%0.3%0.94 $37.09
4/30/20268,604 shares $322.74 thousand -67.6%0.2%0.23 $37.51
4/15/202626,566 shares $1.04 million +511.8%0.6%1.21 $39.00
3/31/20264,342 shares $159.35 thousand -94.1%0.1%0.21 $36.70
3/13/202673,778 shares $2.66 million +602.3%1.5%2.22 $35.99
2/27/202610,506 shares $396.92 thousand -34.3%0.2%0.54 $37.78
2/13/202615,978 shares $583.68 thousand -93.3%0.3%0.76 $36.53
1/30/2026236,844 shares $8.47 million +120.9%5.0%5.42 $35.76
1/15/2026107,213 shares $3.93 million +253.6%2.2%1.42 $36.64
12/31/202530,319 shares $1.05 million +426.1%0.6%0.89 $34.72
12/15/20255,763 shares $201.42 thousand -84.7%0.1%0.2 $34.95
11/28/202537,546 shares $1.34 million +8.3%0.8%1.31 $35.74
11/14/202534,661 shares $1.15 million +695.2%1.2%3.4 $33.19
10/31/20254,359 shares $135.00 thousand -30.0%0.2%0.42 $30.97
10/15/20256,200 shares $187.24 thousand +87.9%0.2%0.7 $30.20
9/30/20253,300 shares $94.68 thousand -73.4%N/A0.4 $28.69
9/15/202512,400 shares $335.93 thousand -82.7%N/A0.7 $27.09
8/31/202571,500 shares $1.90 million +264.8%2.7%4.1 $26.63
8/15/202519,600 shares $523.03 thousand +16.0%N/A1.2 $26.69
7/31/202516,900 shares $437.71 thousand +745.0%0.6%1 $25.90
7/15/20252,000 shares $51.42 thousand -77.8%N/A0.1 $25.71
6/30/20259,000 shares $222.48 thousand +40.6%0.3%0.5 $24.72
6/15/20256,400 shares $162.56 thousand -14.7%0.2%0.7 $25.40
5/31/20257,500 shares $179.78 thousand +92.3%0.3%0.9 $23.97
5/15/20253,900 shares $88.96 thousand -91.9%0.1%0.5 $22.81
4/30/202548,200 shares $1.20 million +1,753.9%N/A6.2 $24.97
4/15/20252,600 shares $59.59 thousand +44.4%0.1%0.3 $22.92
3/31/20251,800 shares $43.44 thousand -18.2%0.1%0.1 $24.14
3/15/20252,200 shares $55.30 thousand -69.4%0.1%0.1 $25.14
2/28/20257,200 shares $184.61 thousand +453.9%0.3%0.4 $25.64
2/15/20251,300 shares $32.68 thousand -92.0%0.1%0.1 $25.14
1/31/202516,300 shares $418.75 thousand +232.7%N/A0.9 $25.69
1/15/20254,900 shares $120.25 thousand -33.8%N/A0.3 $24.54
12/31/20247,400 shares $179.89 thousand +13.9%N/A0.6 $24.31
12/15/20246,500 shares $163.67 thousand +195.5%N/A1.2 $25.18
BSEM Is Officially on Nasdaq... The Next Chapter Begins! (Ad)

BioStem Technologies (NASDAQ: BSEM) debuted on Nasdaq August 7th, marking its move from OTC markets into a new phase of visibility for the regenerative medicine company. The company's acquisition of BioTissue assets expanded its Neox and Clarix product portfolios and strengthened hospital relationships, following seven consecutive profitable quarters and its proprietary BioREtain technology platform. With expanding clinical validation and a focus on the multi-billion-dollar wound care market, BSEM is drawing attention as it scales hospital adoption.tc pixel

See why BioStem Technologies is becoming a closely watched regenerative medicine stock
11/30/20242,200 shares $61.21 thousand +175.0%N/A0.8 $27.82
11/15/2024800 shares $20.95 thousand -20.0%N/A0.3 $26.19
10/31/20241,000 shares $27.62 thousand -37.5%N/A0.3 $27.62
10/15/20241,600 shares $45.71 thousand -30.4%N/A0.4 $28.57
9/30/20242,300 shares $65.34 thousand +283.3%N/A0.5 $28.41
9/15/2024600 shares $17.54 thousand +50.0%N/A0.1 $29.24
8/31/2024400 shares $11.95 thousand -87.9%N/A0 $29.87
8/15/20243,300 shares $94.68 thousand -17.5%N/A0.2 $28.69
7/31/20244,000 shares $117.48 thousand -80.7%N/A0.2 $29.37
7/15/202420,700 shares $607.75 thousand No ChangeN/A1.2 $29.36

CANC Short Interest - Frequently Asked Questions

Short interest is the volume of Tema Oncology ETF shares that have been sold short but have not yet been closed out or covered. As of July 31st, investors have sold 20,291 shares of CANC short. 0.43% of Tema Oncology ETF's shares are currently sold short. Learn More on Tema Oncology ETF's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CANC shares currently have a short interest ratio of 0.9. Learn More on Tema Oncology ETF's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.43% of Tema Oncology ETF's floating shares are currently sold short.

Tema Oncology ETF saw a decline in short interest in July. As of July 31st, there was short interest totaling 20,291 shares, a decline of 11.1% from the previous total of 22,825 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.50 billion), Invesco QQQ ($50.36 billion), iShares Russell 2000 ETF ($21.20 billion), Western Digital Corporation ($13.40 billion), SPDR S&P Biotech ETF ($11.59 billion), Nebius Group N.V. ($11.46 billion), iShares 20+ Year Treasury Bond ETF ($7.84 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($7.51 billion), iShares Semiconductor ETF ($6.37 billion), and Financial Select Sector SPDR Fund ($6.34 billion). View all of the most shorted stocks.

Short selling CANC is an investing strategy that aims to generate trading profit from Tema Oncology ETF as its price is falling. CANC shares are trading down $0.22 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Tema Oncology ETF occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CANC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CANC, twice per month. The most recent reporting period available is July, 31 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like CANC:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:CANC is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 8/11/2026. FINRA publishes updated short interest twice a month.
From Our Partners
BSEM Is Officially on Nasdaq... The Next Chapter Begins!
BioStem Technologies (NASDAQ: BSEM) debuted on Nasdaq August 7th, marking its move from OTC markets into a new...
Huge Alerts | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel